Trials / Completed
CompletedNCT01764321
Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors
A Multi-center, Noninterventional Study With Certolizumab Pegol in Comparison With Any Other Subcutaneous TNF Inhibitor in Two Parallel Groups in Biologic Naive Patients With Rheumatoid Arthritis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,723 (actual)
- Sponsor
- UCB Pharma SA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective, post marketing, observational, Noninterventional Study (NIS) is designed to compare drug persistence in patients treated with Certolizumab Pegol (CZP) and patients treated with any other subcutaneously (sc) administered Tumor Necrosis Factor (TNF) inhibitor.
Conditions
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2020-06-16
- Completion
- 2020-06-16
- First posted
- 2013-01-09
- Last updated
- 2020-12-22
Locations
122 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01764321. Inclusion in this directory is not an endorsement.